AUA 2024 Annual Meeting
Stay up-to-date with the latest coverage of the AUA 2024 Annual Meeting.
Dr. Li provides commentary on the rationale, design, and impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Soon-Shiong provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept for NMIBC.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Dr. Narayan breaks down the 5-year follow-up data on nadofaragene firadenovec for patients with BCG-unresponsive NMIBC.
Development of a novel risk score for early intensification approaches to RT or salvage RT for pN1 receiving RP.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Approximately 82,000 new cases of RCC are diagnosed each year in the US, but effective early detection methods are lacking.
Drs. Murray and Lotan review the development and validation of AI biomarkers to predict outcomes in BCG-treated NMIBC.
Drs. Murray and Lotan highlight a recent multicenter study featuring longitudinal follow-up of UGN-101 for UTUC.
Dr. Spiess highlights prevalence of TERT expression and an increase in TROP-2 mRNA expression levels in PSCC patients.
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
Researchers found increased OS and PFS benefits when patients received nivolumab plus gemcitabine.
New findings from the Nure-Combo trial examined the use of ABX with nivolumab followed by RC and adjuvant nivolumab.
Dr. Lerner shares updates from the ENLIGHTED trial and analyses pertaining to NAC for UTUC from the ROBUUST registry.
Drs. Joyce and Khanna examine the utility of a deep learning algorithm for automated renal volume calculation.
For patients with clinical node-positive UTUC, NAC may lead to improved outcomes compared with adjuvant chemotherapy.
ICIs improves OS for patients with mRCC and sarcomatoid features who undergo CN, regardless of the timing of surgery.
Padeliporfin VTP has previously shown positive safety and efficacy results for patients with low-grade UTUC.
Drs. Joyce and Pierorazio weigh appropriate surveillance versus primary intervention for clinical T1a kidney tumors.
Researchers compared open cystectomy with a robotic approach to determine differences between the 2 procedures.
RT to recurrence sites may not have an effect on oncologic outcomes in patients with MIBC after RC.
The utility of cADT in patients with prostate cancer with clinical relapse at PSMA PET is unknown.
Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM.
Researchers completed a comprehensive evaluation of features that can serve as biomarkers of response to ICB therapy in mRCC.
The primary end point was establishing the risk of relapse connected with both surgical approaches.
The study group received 6-month neoadjuvant LHRH-α plus abitrexone with prednisone.
Intravesical EMDA/MMC can serve as a safe and effective option for patients with high-risk NMIBC who fail BCG therapy.
A phase 2 clinical trial assessed combination intravesical gemcitabine and docetaxel for BCG-naïve NMIBC.
uMRD profiling determines mutations connected with urothelial carcinoma through next-generation sequencing.
Researchers sought to determine if ctDNA detection before cystectomy is linked to poor outcomes and lymph node involvement.
Identifying tumor biomarkers associated with pCR to neoadjuvant pembro or NAC prior to cystectomy in patients with MIBC.
Results from the third interim analysis of the DAROL study indicate real-world effectiveness in patients with nmCRPC.
Patients received weekly doses of docetaxel 80 mg, gemcitabine 1000 mg or 2000 mg, and biweekly cisplatin 100 mg.
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Advertisement
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get conference updates straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.